The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma
BackgroundTumor-infiltrating immune cells are important components of tumor microenvironment (TME), and their composition reflects the confrontation between host immune system and tumor cells. However, the relationship between the composition of infiltrating immune cells, prognosis, and the applicab...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.744951/full |
id |
doaj-d302ec90e6af4b8cacc15a99c6eeee3c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Jianxiang Chen Jianxiang Chen Jianxiang Chen Jianxiang Chen Dalong Wan Lin Zhou Lin Zhou Lin Zhou Lin Zhou Shusen Zheng Shusen Zheng Shusen Zheng Shusen Zheng Shusen Zheng Yiting Qiao Yiting Qiao Yiting Qiao Yiting Qiao |
spellingShingle |
Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Jianxiang Chen Jianxiang Chen Jianxiang Chen Jianxiang Chen Dalong Wan Lin Zhou Lin Zhou Lin Zhou Lin Zhou Shusen Zheng Shusen Zheng Shusen Zheng Shusen Zheng Shusen Zheng Yiting Qiao Yiting Qiao Yiting Qiao Yiting Qiao The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma Frontiers in Oncology HCC CIBERSORT PD-L1 immune subtype prognosis |
author_facet |
Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Jiacheng Huang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Lele Zhang Jianxiang Chen Jianxiang Chen Jianxiang Chen Jianxiang Chen Dalong Wan Lin Zhou Lin Zhou Lin Zhou Lin Zhou Shusen Zheng Shusen Zheng Shusen Zheng Shusen Zheng Shusen Zheng Yiting Qiao Yiting Qiao Yiting Qiao Yiting Qiao |
author_sort |
Jiacheng Huang |
title |
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma |
title_short |
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma |
title_full |
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma |
title_fullStr |
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma |
title_full_unstemmed |
The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma |
title_sort |
landscape of immune cells indicates prognosis and applicability of checkpoint therapy in hepatocellular carcinoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
BackgroundTumor-infiltrating immune cells are important components of tumor microenvironment (TME), and their composition reflects the confrontation between host immune system and tumor cells. However, the relationship between the composition of infiltrating immune cells, prognosis, and the applicability of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma (HCC) needs systematic examination.MethodsCell-Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) was applied to evaluate the infiltration of immune cells based on The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) cohort. Diagnostic and prognostic models were constructed based on immune cells, and the models were validated by two external cohorts. The relationship between immune cells and PD-L1 was evaluated by Spearman correlation, and the finding was validated in our in-house HCC sample.ResultPatients in TCGA LIHC cohort were classified into six subtypes with different prognosis based on the proportion of tumor-infiltrating immune cells simulated via CIBERSORT. Among 22 types of immune cells, intratumoral PD-L1 mRNA level exhibited linear relationship with the fraction of five types of immune cells (M1 macrophages, plasma cells, CD8+ T cells, resting mast cells, and regulatory T cells), and M1 macrophages showed the strongest relevance (R = 0.26, p < 0.001). Immunohistochemistry of our in-house HCC specimens verified this conclusion. Moreover, intratumoral mRNA levels of M1 macrophage-associated cytokines were positively correlated with PD-L1 level.ConclusionsOur study demonstrated that the prognosis of HCC patients was associated with the pattern of infiltrating immune cells in TME, and macrophage-associated cytokines might be a potential non-invasive marker for predicting the PD-L1 level for HCC patients. |
topic |
HCC CIBERSORT PD-L1 immune subtype prognosis |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.744951/full |
work_keys_str_mv |
AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jianxiangchen thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jianxiangchen thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jianxiangchen thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jianxiangchen thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT dalongwan thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT linzhou thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT linzhou thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT linzhou thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT linzhou thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT yitingqiao thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT yitingqiao thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT yitingqiao thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT yitingqiao thelandscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jiachenghuang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT lelezhang landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jianxiangchen landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jianxiangchen landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jianxiangchen landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT jianxiangchen landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT dalongwan landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT linzhou landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT linzhou landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT linzhou landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT linzhou landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT shusenzheng landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT yitingqiao landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT yitingqiao landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT yitingqiao landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma AT yitingqiao landscapeofimmunecellsindicatesprognosisandapplicabilityofcheckpointtherapyinhepatocellularcarcinoma |
_version_ |
1716866361664208896 |
spelling |
doaj-d302ec90e6af4b8cacc15a99c6eeee3c2021-09-28T06:48:14ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.744951744951The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular CarcinomaJiacheng Huang0Jiacheng Huang1Jiacheng Huang2Jiacheng Huang3Jiacheng Huang4Jiacheng Huang5Lele Zhang6Lele Zhang7Lele Zhang8Lele Zhang9Lele Zhang10Lele Zhang11Jianxiang Chen12Jianxiang Chen13Jianxiang Chen14Jianxiang Chen15Dalong Wan16Lin Zhou17Lin Zhou18Lin Zhou19Lin Zhou20Shusen Zheng21Shusen Zheng22Shusen Zheng23Shusen Zheng24Shusen Zheng25Yiting Qiao26Yiting Qiao27Yiting Qiao28Yiting Qiao29Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSchool of Medicine, Zhejiang University, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSchool of Medicine, Zhejiang University, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, ChinaPharmacy Institute and Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, ChinaKey Laboratory of Elemene Class Anti-Cancer Medicine of Zhejiang Province, Hangzhou, ChinaEngineering Laboratory of Development and Application of Chinese Medicine from Zhejiang Province, Hangzhou, China0Collaborative Innovation Center of Chinese Medicines from Zhejiang Province, School of Medicine, Hangzhou Normal University, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, ChinaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaNational Health Center (NHC) Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Research Center for Diagnosis and Treatment of Hepatobiliary Diseases, Hangzhou, ChinaBackgroundTumor-infiltrating immune cells are important components of tumor microenvironment (TME), and their composition reflects the confrontation between host immune system and tumor cells. However, the relationship between the composition of infiltrating immune cells, prognosis, and the applicability of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma (HCC) needs systematic examination.MethodsCell-Type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) was applied to evaluate the infiltration of immune cells based on The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) cohort. Diagnostic and prognostic models were constructed based on immune cells, and the models were validated by two external cohorts. The relationship between immune cells and PD-L1 was evaluated by Spearman correlation, and the finding was validated in our in-house HCC sample.ResultPatients in TCGA LIHC cohort were classified into six subtypes with different prognosis based on the proportion of tumor-infiltrating immune cells simulated via CIBERSORT. Among 22 types of immune cells, intratumoral PD-L1 mRNA level exhibited linear relationship with the fraction of five types of immune cells (M1 macrophages, plasma cells, CD8+ T cells, resting mast cells, and regulatory T cells), and M1 macrophages showed the strongest relevance (R = 0.26, p < 0.001). Immunohistochemistry of our in-house HCC specimens verified this conclusion. Moreover, intratumoral mRNA levels of M1 macrophage-associated cytokines were positively correlated with PD-L1 level.ConclusionsOur study demonstrated that the prognosis of HCC patients was associated with the pattern of infiltrating immune cells in TME, and macrophage-associated cytokines might be a potential non-invasive marker for predicting the PD-L1 level for HCC patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.744951/fullHCCCIBERSORTPD-L1immune subtypeprognosis |